department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Olema Pharmaceuticals, Inc. ($OLMA) · pharmadog

PUBLIC COMPANY

$OLMAOlema Pharmaceuticals, Inc.

San Francisco, CA, USupdated 1mo ago

SEC EDGAR ↗Yahoo Finance ↗

community read0 votes

pipeline

2

marketed

0

phase 3

1

catalysts ytd

0

approvals ytd

0

recalls ytd

0

Pipeline(2)

pipeline depth2 products

1Phase 11Phase 3

Human Epidermal Growth Factor Receptor 2 Negative Breast…

Human Epidermal Growth Factor Receptor 2 Negative Breast…

Upcoming

no upcoming catalysts on record

Recent(90d)

nothing in the last 90 days

view all catalysts →

🐶 Hiring Signal

No open roles indexed yet — view Olema Pharmaceuticals, Inc. jobs →

News

no news has mentioned this company yet

identifiers

ticker

$OLMA

SEC CIK

0001750284

country

US

source

sec_tickers

top tags

Oncology2 NSCLC1

mentioned in

0news items

entity-linker matched

$OLMA

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Active trials

phase3Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancerrecruitingn=1,000
phase3OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancerrecruitingn=510
phase1A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patientsactive not recruitingn=60
phase1Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancerrecruitingn=190
phase1Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumorsrecruitingn=180
phase2A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancercompletedn=153

Data sources

last refreshed 52m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Insider activity

source: SEC Form 4

open-market buys + sells

Mar 4, 26SELLMitchell Shawnte· CHIEF LEGAL OFFICER24,767 sh @ $24.25−$601K↗
Mar 4, 26SELLMitchell Shawnte· CHIEF LEGAL OFFICER233 sh @ $24.69−$6K↗
Mar 3, 26SELLMitchell Shawnte· CHIEF LEGAL OFFICER

15,000 sh @ $23.01

−$345K

routine RSU / option mechanics (6)

Mar 4, 26option exerciseMitchell Shawnte · CHIEF LEGAL OFFICER25,000 sh
Mar 4, 26option exerciseMitchell Shawnte · CHIEF LEGAL OFFICER25,000 sh
Mar 3, 26option exerciseMitchell Shawnte · CHIEF LEGAL OFFICER15,000 sh
Mar 3, 26option exerciseMitchell Shawnte · CHIEF LEGAL OFFICER15,000 sh
Feb 2, 26grantMitchell Shawnte · CHIEF LEGAL OFFICER220,000 sh
Feb 2, 26grantMitchell Shawnte · CHIEF LEGAL OFFICER56,250 sh